Terra Venture Partners

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Retrieved on: 
Friday, November 10, 2023
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Medicine, AstraZeneca, Biostatistics, Therapy, University of Queensland, University, Research, Bristol Myers Squibb, OrbiMed, MBBS, Terra Venture Partners, MD, Drug discovery, Growth, Synthetic biology, Cytosol, GSK plc, Enzyme, Drug development, Pharmaceutical industry, Epidemiology

NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.

Key Points: 
  • NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.
  • Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
  • Most recently, Tony held the position of Chief Executive Officer at Goldfinch Bio and is Chair of the Board of Directors at Outrun Therapeutics.
  • Tony brings extensive and broad expertise to NanoSyrinx, particularly in drug discovery and early clinical development.

Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models

Retrieved on: 
Thursday, December 14, 2023
ZINC, Terra Venture Partners, Partner (business rank), SAN, Therapy, UCSF, Inflammation, Doctor of Philosophy, Obesity, G protein-coupled receptor, DSM-IV codes, Stanford University, University, Drug discovery, Deep learning, ATP, GPCR, Fine chemical

SAN FRANCISCO and NEW YORK, Dec. 14, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, today announced $52 million in Series A funding for its portfolio company Deep Apple Therapeutics, created and incubated by ATP to rapidly discover novel small molecule therapeutics for high-value targets through virtual screening of AI-generated virtual libraries. With a powerful discovery engine that combines ensemble cryo-EM, deep learning, and molecular docking screens of ultra-large libraries, Deep Apple can go from target identification to lead optimization in less than 12 months – a fraction of the industry standard time – and can pursue biological target signaling inaccessible to conventional discovery approaches. Deep Apple's discovery engine is broadly applicable across disease areas and is particularly well-suited to expedited hit-finding against integral membrane proteins. The company currently is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.

Key Points: 
  • Deep Apple's discovery engine is broadly applicable across disease areas and is particularly well-suited to expedited hit-finding against integral membrane proteins.
  • "ATP created Deep Apple to revolutionize drug discovery in terms of speed, cost, and effectiveness," said Spiros Liras, Ph.D., founding CEO of Deep Apple and a Venture Partner at ATP.
  • And our virtual large-scale docking enables us to quickly home in on the right drug for the right target."
  • Wet-lab interrogations of the chosen virtual compounds feed back into the company's deep learning models to continually improve predictive performance.

TDK Ventures invests in Peak Energy to advance sodium-ion energy storage solutions

Retrieved on: 
Wednesday, October 4, 2023
Eclipse, Partnership, EV, TDK, Terra Venture Partners, Peak, Energy, LFP, CCO, NMC, ESS, Climate change, SAN, SIB, Sodium, Safety, TSE, Lithium, Electric battery, Renewable energy, Cloud Peak Energy

Peak Energy's groundbreaking approach provides innovative, resilient, and domestically sourced energy storage while offering a safety net against increasing energy demands, supply chain volatility, and climate change concerns.

Key Points: 
  • Peak Energy's groundbreaking approach provides innovative, resilient, and domestically sourced energy storage while offering a safety net against increasing energy demands, supply chain volatility, and climate change concerns.
  • By 2030, it is estimated that the United States will require a staggering 600 GWh of energy storage, translating into a market value of approximately $40 billion.
  • "Peak Energy aligns perfectly with TDK Ventures' strategic focus on both societal impact, sustainable progress, and venture-style financial return," said Nicolas Sauvage, President of TDK Ventures.
  • "With TDK Ventures' investment and support, Peak Energy is taking a major step towards our goal of building a scalable, resilient and domestically produced battery storage solution with substantial environmental and supply chain security benefits."

Mojave Raises $12.5M from Fifth Wall, At One Ventures, Xerox Ventures to Change the Nature of Air Conditioning

Retrieved on: 
Monday, September 18, 2023
Palo Alto, California, Maintenance, Version One Ventures, Dedicated outdoor air system, Atmosphere, Terra Venture Partners, Research, Carbon, Global warming potential, The Writing on the Wall, HVAC, School, Humidity, Hospital, Partner, DOAS, PARC, Heat, Bacteria, Virus, Heating, ventilation, and air conditioning, Renewable energy

SUNNYVALE, Calif., Sept. 18, 2023 /PRNewswire/ -- Today, Mojave Energy Systems announces its $12.5 million seed round of funding that will be used to launch its third-generation liquid desiccant air conditioning platform.

Key Points: 
  • The novel Mojave product cuts in half the energy required to provide buildings with fresh, cool, and dry outdoor air.
  • The round is co-led by At One Ventures and Fifth Wall with participation from Xerox Ventures and others.
  • "Today the story is about dehumidification, not cooling; in fact, we spend more energy dehumidifying air than we do cooling it.
  • The biocidal properties of its liquid desiccant even purify the air from bacteria and viruses further improving air quality.

Rocsys Secures €33M to Redefine the EV Charging Experience with Autonomous Charging, Powered by AI and Robotics

Retrieved on: 
Tuesday, July 11, 2023
EV, Mercedes-Benz, BofA Securities, Investment, Terra Venture Partners, Original equipment manufacturer, Policy, Ford, Research, Rocsi Diaz, Central Waqf Council, Friction, AUDI, BMW, Risk, InvestEU, Engineering, Series, European, SEB, Growth, Transport, Robotics, European Investment Bank, CO2, Renewable energy, Porsche

Rocsys combines soft robotics, AI-based computer vision, and data-driven services to easily adapt existing chargers into an autonomous system that can plug in and out without manual intervention.

Key Points: 
  • Rocsys combines soft robotics, AI-based computer vision, and data-driven services to easily adapt existing chargers into an autonomous system that can plug in and out without manual intervention.
  • “Rocsys makes electrification practical for vehicles ranging from personal autonomous cars to continuously operating heavy-duty equipment, a major source of emissions.
  • “Rocsys is transforming the EV charging experience by creating an easy-to-use and scalable solution,” said Frederik Gerner, Venture Partner at Forward.One.
  • To learn more about Rocsys’ approach and the benefits of autonomous charging, visit www.rocsys.com .

Rocsys Secures $36M to Redefine the EV Charging Experience with Autonomous Charging, Powered by AI and Robotics

Retrieved on: 
Tuesday, July 11, 2023
EV, Mercedes-Benz, BofA Securities, Investment, Terra Venture Partners, Original equipment manufacturer, Policy, Ford, Research, Rocsi Diaz, Central Waqf Council, Friction, AUDI, BMW, Risk, InvestEU, Engineering, Series, European, SEB, Growth, Transport, Robotics, European Investment Bank, CO2, Renewable energy, Porsche

Rocsys combines soft robotics, AI-based computer vision, and data-driven services to easily adapt existing chargers into an autonomous system that can plug in and out without manual intervention.

Key Points: 
  • Rocsys combines soft robotics, AI-based computer vision, and data-driven services to easily adapt existing chargers into an autonomous system that can plug in and out without manual intervention.
  • “Rocsys makes electrification practical for vehicles ranging from personal autonomous cars to continuously operating heavy-duty equipment, a major source of emissions.
  • “Rocsys is transforming the EV charging experience by creating an easy-to-use and scalable solution,” said Frederik Gerner, Venture Partner at Forward.One.
  • To learn more about Rocsys’ approach and the benefits of autonomous charging, visit www.rocsys.com .

Venture For ClimateTech Selects 20 Early-Stage Companies to Advance Innovations, Reduce Carbon Emissions, and Fight Climate Change

Retrieved on: 
Tuesday, June 13, 2023
Cohort, Nitrous oxide, Sunlight, Laboratory for Laser Energetics, Haber process, Transport, Terra Venture Partners, University, EV, Electronics, Heliotrope, ARPA, HVAC, Ammonia, Machine learning, Solar energy, Climate, Nitrogen, Capital expenditure, MIT, Carbon, Automation, Climate change, Battery, NYSERDA, Water resources, Hydrogen, Tree, Tenant, Public expenditure, Solarmer Energy, Inc., Silicon, Active surface, CO2, Renewable energy, Fertilizer, Electric battery, ISR

ROCHESTER, N.Y., June 13, 2023 (GLOBE NEWSWIRE) -- Venture For ClimateTech has selected 20 early-stage companies to participate in its third cohort and advance innovations to reduce carbon emissions and fight climate change.

Key Points: 
  • ROCHESTER, N.Y., June 13, 2023 (GLOBE NEWSWIRE) -- Venture For ClimateTech has selected 20 early-stage companies to participate in its third cohort and advance innovations to reduce carbon emissions and fight climate change.
  • Venture For ClimateTech is a global non-profit venture studio + accelerator that removes obstacles that new innovators face when trying to bring ideas to market.
  • This year, the program is doubling the size of its cohort from an average of 10 companies to 20.
  • With this track record of Venture For ClimateTech, we’re confident in scaling our program to serve even more early-stage companies,” said Jack Baron, Venture For ClimateTech’s managing director.

Danaher Cryogenics Secures CRADA with NIST to Commercially Develop the Most Advanced High-Performance Pulse Tube Cryocooler to Date

Retrieved on: 
Wednesday, May 17, 2023
ACT, NIST, Partnership, University, CRADA, Terra Venture Partners, CU, Development, University of Colorado Boulder, CO, Cooperative research and development agreement, National Institute of Standards and Technology, Engineering, Industrial gas

This state-of-the-art pulse tube cryocooler holds the promise of offering the most rapid cooldown performance technology in the industry.

Key Points: 
  • This state-of-the-art pulse tube cryocooler holds the promise of offering the most rapid cooldown performance technology in the industry.
  • Working via a Cooperative Research and Development Agreement (CRADA), Danaher Cryogenics is partnering with the National Institute of Standards and Technology (NIST) in Boulder, CO to commercially develop this exciting new product.
  • "Danaher Cryogenics is proud to be partnering with NIST and CU Boulder to commercialize the new Adaptive Cooling Technology for Pulse Tube Refrigerators," said Charlie Danaher, President and Founder of Danaher Cryogenics.
  • The commercial development of the Danaher Cryogenics ACT Pulse Tube Cryocooler is already underway.

Surgical Safety Technologies Furthers its Mission of Improving Operating Room Safety and Efficiency With $15 Million in Series A Funding

Retrieved on: 
Thursday, May 4, 2023
USVP, Checklist, Vehicle safety technology, SST, Accreditation, VMware Carbon Black, World Health Organization ranking of health systems in 2000, OR, Black box, General partnership, Terra Venture Partners, Operating, Hospital, Patient, U.S. Venture Partners, Knowledge, Trauma, Benchmarking, Clinical, Safety, Medical device, Nursing

TORONTO and NEW YORK, May 4, 2023 /PRNewswire/ -- Surgical Safety Technologies (SST), a medical technology company that engineered the OR Black Box® platform for hospitals, has today announced $15 Million in Series A funding. The round was led by U.S. Venture Partners and Santé Ventures, and will be used to accelerate the company's automation initiatives and commercial efforts. SST's platform leverages AI both to inform real-time decision making and provide analytical insight in the areas of safety, compliance and efficiency, which drastically improves patient outcomes and reduces hospital costs.

Key Points: 
  • SST's platform leverages AI both to inform real-time decision making and provide analytical insight in the areas of safety, compliance and efficiency, which drastically improves patient outcomes and reduces hospital costs.
  • "I am honored to have this support and confidence as we continue our mission of making healthcare safer and more cost-effective," noted Teodor Grantcharov, founder of Surgical Safety Technologies.
  • Surgical Safety Technologies is developing the operating room of the future, with products that are consistent with Santé's mission of investing in health technologies making meaningful patient impact."
  • For more information about SST and how the company is improving surgical outcomes for patients across the world, please visit www.surgicalsafety.com .

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer

Retrieved on: 
Thursday, April 20, 2023
Oncology, Health, Radiology, Research, Science, Pharmaceutical, Biotechnology, PK, Carcinoma, Drug development, Doctor of Philosophy, Investment, Radionuclide, Venture round, Beta, Food, Therapeutic index, ADMAR, Viking Global Investors, Cancer, Bone marrow, Record, Radiochemistry, Radiopharmaceutical, Antibody, Terra Venture Partners, SCLC, AbCellera, DLL3, Protein, Patient, Kidney, Neoplasm, FDA, Therapy, IND, Regulation of tobacco by the U.S. Food and Drug Administration, FC, Radio, Isotope, Medical imaging, Management

Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced it has raised $142 million in combined Series A and B financing.

Key Points: 
  • Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced it has raised $142 million in combined Series A and B financing.
  • “Abdera’s ROVEr™ platform enables the design of antibody-based radiopharmaceuticals that are ideally suited to specific cancer targets with optimized PK properties to pair with a radioisotope of choice and maximize therapeutic impact.
  • “DLL3 is a well-validated target for SCLC, a cancer with few treatment options,” said Yvonne Yamanaka, Ph.D., principal, venBio Partners.
  • “We are pleased to have worked with the company’s talented co-founders to grow Abdera and we look forward to what this team can achieve.